Kohl T. Kinning

Kohl T. Kinning

Auto-generated profile, based on publicly available information

Kohl T. Kinning

Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2023 in Nature Genetics
Verified
Journal Article
Open access
PDF file
KWKatherine A. Waugh
Katherine A. Waugh
RMRoss Minter
Ross Minter
JBJessica Baxter
Jessica Baxter
CCCongwu Chi
Congwu Chi
MGMatthew D. Galbraith
Matthew D. Galbraith
JEJoaquin M. Espinosa
Joaquin M. Espinosa
Down syndrome (DS), the genetic condition caused by trisomy 21, is characterized by variable cognitive impairment, immune dysregulation, dysmorphogenesis and increased prevalence of diverse co-occurring conditions. The mechanisms by which trisomy 21 causes these effects remain largely unknown. We demonstrate that triplication of the interferon receptor (IFNR) gene cluster on chromosome 21 is necessary for multiple phenotypes in a mouse model of DS. Whole-blood transcriptome analysis demonstrated that IFNR overexpression associates with chronic interferon hyperactivity and inflammation in people with DS. To define the contribution of this locus to DS phenotypes, we used genome editing to correct its copy number in a mouse model of DS, which normalized antiviral responses, prevented heart malformations, ameliorated developmental delays, improved cognition and attenuated craniofacial anomalies. Triplication of the Ifnr locus modulates hallmarks of DS in mice, suggesting that trisomy 21 elicits an interferonopathy potentially amenable to therapeutic intervention.

30 June 2023 in Science Advances
Verified
Journal Article
Open access
MGMatthew D. Galbraith
Matthew D. Galbraith
ARAngela L. Rachubinski
Angela L. Rachubinski
KSKeith P. Smith
Keith P. Smith
PAPaula Araya
Paula Araya
KWKatherine A. Waugh
Katherine A. Waugh
JEJoaquin M. Espinosa
Joaquin M. Espinosa
Individuals with Down syndrome (DS) display chronic hyperactivation of interferon signaling. However, the clinical impacts of interferon hyperactivity in DS are ill-defined. Here, we describe a multiomics investigation of interferon signaling in hundreds of individuals with DS. Using interferon scores derived from the whole blood transcriptome, we defined the proteomic, immune, metabolic, and clinical features associated with interferon hyperactivity in DS. Interferon hyperactivity associates with a distinct proinflammatory phenotype and dysregulation of major growth signaling and morphogenic pathways. Individuals with the highest interferon activity display the strongest remodeling of the peripheral immune system, including increased cytotoxic T cells, B cell depletion, and monocyte activation. Interferon hyperactivity accompanies key metabolic changes, most prominently dysregulated tryptophan catabolism. High interferon signaling stratifies a subpopulation with elevated rates of congenital heart disease and autoimmunity. Last, a longitudinal case study demonstrated that JAK inhibition normalizes interferon signatures with therapeutic benefit in DS. Together, these results justify the testing of immune-modulatory therapies in DS.

25 February 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MGMatthew D. Galbraith
Matthew D. Galbraith
KKKohl T. Kinning
Kohl T. Kinning
KSKelly D. Sullivan
Kelly D. Sullivan
PAPaula Araya
Paula Araya
KSKeith P. Smith
Keith P. Smith
JEJoaquin M. Espinosa
Joaquin M. Espinosa
Significance: The interferon (IFN) family of proteins plays key roles in the immune response against viruses and other pathogens. In the context of COVID-19, IFNs have been shown to be key for restraining SARS-CoV-2 infection but have also been described as drivers of severe symptoms. However, it is not fully understood how each member of the IFN family contributes to distinct aspects of COVID-19. We report here the results of a deep examination of 12 different IFNs in hospitalized COVID-19 patients, which revealed clear differences among IFNs in their associations with molecular, cellular, and physiological processes relevant to COVID-19 presentation.

31 March 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
LLL. Alexander Liggett
L. Alexander Liggett
MGMatthew D. Galbraith
Matthew D. Galbraith
KSKeith P. Smith
Keith P. Smith
KSKelly D. Sullivan
Kelly D. Sullivan
RGRoss E. Granrath
Ross E. Granrath
JDJames DeGregori
James DeGregori
Key Points: Children with Down syndrome develop early signs of clonal evolution that resemble traditional clonal hematopoiesis. Children with trisomy 21 who exhibit clonal hematopoiesis display cytokine and gene expression profiles indicative of disrupted immunity.

1 January 2021 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
KSKelly D. Sullivan
Kelly D. Sullivan
MGMatthew D. Galbraith
Matthew D. Galbraith
KKKohl T. Kinning
Kohl T. Kinning
KBKyle Bartsch
Kyle Bartsch
NLNik Levinsky
Nik Levinsky
JEJoaquin M. Espinosa
Joaquin M. Espinosa
COVID-19 pathology involves dysregulation of diverse molecular, cellular, and physiological processes. In order to expedite integrated and collaborative COVID-19 research, we completed multi-omics analysis of hospitalized COVID-19 patients including matched analysis of the whole blood transcriptome, plasma proteomics with two complementary platforms, cytokine profiling, plasma and red blood cell metabolomics, deep immune cell phenotyping by mass cytometry, and clinical data annotation. We refer to this multidimensional dataset as the COVIDome. We then created the COVIDome Explorer, an online researcher portal where the data can be analyzed and visualized in real time. We illustrate here the use of the COVIDome dataset through a multi-omics analysis of biosignatures associated with C-reactive protein (CRP), an established marker of poor prognosis in COVID-19, revealing associations between CRP levels and damage-associated molecular patterns, depletion of protective serpins, and mitochondrial metabolism dysregulation. We expect that the COVIDome Explorer will rapidly accelerate data sharing, hypothesis testing, and discoveries worldwide. Funding: This work was supported by NIH grants R01AI150305, 3R01AI150305-01S1, R01AI145988, UL1TR002535, 3UL1TR002535-03S2, R01HL146442, R01HL149714, R01HL148151, R21HL150032, P30CA046934, R35GM124939 and RM1GM131968, as well as grants from the Boettcher Foundation and Fast Grants. Additional support was received from Chancellor’s Discovery Innovation Fund at the CU Anschutz Medical Campus, the Global Down Syndrome Foundation, the Anna and John J. Sie Foundation, and Lyda Hill Philanthropies. Conflict of Interest: KDS and JME are co-inventors on two patents related to JAK inhibition in COVID-19; JME serves in the COVID Development Advisory Board for Elly Lilly and has provided consulting services to Gilead Sciences Inc. JME serves on the Cell Reports Advisory Board.